NGM Bio Announces Pricing of Initial Public Offering Portfolio News / admin April 3, 2019 NGM Bio Announces Pricing of Initial Public Offering Read More »
Gritstone Oncology Announces First Patient Dosed in a Clinical Study Evaluating its Personalized Immunotherapy, GRANITE-001 Portfolio News / admin March 21, 2019 Gritstone Oncology Announces First Patient Dosed in a Clinical Study Evaluating its Personalized Immunotherapy, GRANITE-001 Read More »
NGM Bio Appoints Hsiao D. Lieu, M.D. as SVP, Chief Medical Officer and Alex DePaoli, M.D. to New Role of SVP, Chief Translational Officer Portfolio News / admin March 20, 2019 NGM Bio Appoints Hsiao D. Lieu, M.D. as SVP, Chief Medical Officer and Alex DePaoli, M.D. to New Role of SVP, Chief Translational Officer Read More »
Surrozen Raises $50 Million in Series B Financing to Advance Regenerative Antibody Platforms and Liver Disease Candidate Portfolio News / admin March 14, 2019 Surrozen Raises $50 Million in Series B Financing to Advance Regenerative Antibody Platforms and Liver Disease Candidate Read More »
Immune Design acquired by Merck for approx. $300M Portfolio News / admin February 21, 2019 Immune Design acquired by Merck for approx. $300M Read More »
Kallyope Inc. Appoints Brett Lauring as Chief Medical Officer Portfolio News / admin February 5, 2019 Kallyope Inc. Appoints Brett Lauring as Chief Medical Officer Read More »
Ribon Therapeutics Raises $65 Million to Advance Pipeline of Novel Therapeutics Targeting Cellular Stress Pathways for Cancer Portfolio News / admin January 4, 2019 Ribon Therapeutics Raises $65 Million to Advance Pipeline of Novel Therapeutics Targeting Cellular Stress Pathways for Cancer Read More »
Constellation Pharmaceuticals Provides Update on MANIFEST Clinical Trial of CPI-0610 in Myelofibrosis, Reviews 2018 Accomplishments, and Announces 2019 Data Disclosure Plans for Lead Programs Portfolio News / admin January 3, 2019 Constellation Pharmaceuticals Provides Update on MANIFEST Clinical Trial of CPI-0610 in Myelofibrosis, Reviews 2018 Accomplishments, and Announces 2019 Data Disclosure Plans for Lead Programs Read More »
Merck Exercises Option for NGM Bio’s Investigational Insulin Sensitizer, NGM313, for the Treatment of NASH and Type 2 Diabetes Portfolio News / admin January 3, 2019 Merck Exercises Option for NGM Bio’s Investigational Insulin Sensitizer, NGM313, for the Treatment of NASH and Type 2 Diabetes Read More »